Email
TextLatest News on Clinical Trials
Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the completion of dosing in its Phase 1 trial of stem cell mobilization therapy...
Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial
Expansion Phase to Evaluate CTLA-4-Directed Probody® Therapeutic in Combination with Opdivo® in Metastatic Melanoma Bristol-Myers Squibb also AdvancesBMS-986288 into a Separate Phase 1/2a Clinical Trial SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) --...
Aldeyra Therapeutics to Provide Update on Late-Stage Clinical Development Pipeline at 2020 Research & Development Day
Primary Endpoint of Symptom Control Achieved in Phase 2 Dry Eye Disease Formulation Clinical Trial Statistically Significant Combined Data Across Multiple Dry Eye Disease Clinical Trials Suggests Potential Early and Potent Activity in Signs and Symptoms In...
Pandion Announces First Subject Dosed in a Phase 1 Clinical Trial of PT101, an IL-2 Mutein Fc Fusion Therapy for Autoimmune Disease
Pandion Therapeutics, Inc., a biotechnology company developing modular protein therapeutics for autoimmune disease, today announced the dosing of the first subject in a Phase 1 clinical trial of PT101, a novel and proprietary interleukin 2 (IL-2) mutein Fc fusion...
Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes
Sojournix, a clinical-stage biopharmaceutical company developing transformative medicines for women’s health and neuroendocrine disorders, today announced the initiation of a Phase 2 trial of SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist in...
Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions
SAN JOSE, Calif., Feb. 20, 2020 /PRNewswire/ -- Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced that positive six-month results from the Peregrine Post-Market Study demonstrating the safety and efficacy...
Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases,...
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
GAINESVILLE, Fla.--(BUSINESS WIRE)--Feb 20, 2020-- Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that...
Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication of results from...
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient...
ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program
VICTORIA, Feb. 20, 2020 /PRNewswire/ - ImmunoPrecise Antibodies Ltd (the "Company"), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, announces its commitment to the development of innovative vaccines against the new...
VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel, Feb. 20, 2020 (GLOBE...
CytoDyn Receives Institutional Review Board Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers
VANCOUVER, Washington, Feb. 21, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported...
CITrials Conducts Highly Reliable Clinical Trials for People with Arthritis Diseases
Santa Ana, CA -- (SBWIRE) -- 02/20/2020 -- Arthritis is one of the most leading causes of pain and disability worldwide. There are more than 100 different types of arthritis and related diseases. However, the most common types of arthritis are osteoarthritis and...
Agenus Announces Positive Interim Data from Balstilimab and Zalifrelimab Clinical Trials in Second-Line Cervical Cancer
- Balstilimab and zalifrelimab combination yield >20% response rates - Balstilimab and zalifrelimab combination has best-in-class potential for the treatment of second-line cervical cancer - On track to submit 2 BLAs for these agents in 2020 - Low-dose AGEN1181...
NoNO Inc. Reports Groundbreaking Results from the Phase 3 ESCAPE-NA1 Study of the Peptide, Nerinetide, in Acute Ischemic Stroke
The novel peptide nerinetide, without prior administration of alteplase, improved functional outcome, reduced mortality and reduced infarct volume among acute ischemic stroke patients Data presented at the plenary session of the International Stroke Conference 2020...
Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases,...
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed...
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria
CHARLOTTESVILLE, VA / ACCESSWIRE / February 19, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approval to commence its...
VBL Therapeutics Announces the Launch of a New Clinical Trial of VB-111 Combined with the Checkpoint Inhibitor, Nivolumab, in Metastatic Colorectal Cancer
This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel, Feb. 20, 2020 (GLOBE...